MX2022011973A - Composiciones de proteina anti-vegf y metodos para producir la misma. - Google Patents

Composiciones de proteina anti-vegf y metodos para producir la misma.

Info

Publication number
MX2022011973A
MX2022011973A MX2022011973A MX2022011973A MX2022011973A MX 2022011973 A MX2022011973 A MX 2022011973A MX 2022011973 A MX2022011973 A MX 2022011973A MX 2022011973 A MX2022011973 A MX 2022011973A MX 2022011973 A MX2022011973 A MX 2022011973A
Authority
MX
Mexico
Prior art keywords
producing
methods
same
protein compositions
vegf protein
Prior art date
Application number
MX2022011973A
Other languages
English (en)
Inventor
Andrew Tustian
Erica Pyles
Nisha Palackal
Ankit Vartak
Thomas Daly
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=76210828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022011973(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022011973A publication Critical patent/MX2022011973A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/80—Fraction collectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C12N2529/10—Stimulation by light
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden proteínas anti-VEGF y métodos para producir tales composiciones.
MX2022011973A 2019-12-06 2021-12-02 Composiciones de proteina anti-vegf y metodos para producir la misma. MX2022011973A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962944635P 2019-12-06 2019-12-06
US202063065012P 2020-08-13 2020-08-13

Publications (1)

Publication Number Publication Date
MX2022011973A true MX2022011973A (es) 2022-11-09

Family

ID=76210828

Family Applications (10)

Application Number Title Priority Date Filing Date
MX2021014862A MX2021014862A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022006788A MX2022006788A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2021014863A MX2021014863A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022006759A MX2022006759A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022006758A MX2022006758A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022006760A MX2022006760A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022011973A MX2022011973A (es) 2019-12-06 2021-12-02 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2023005421A MX2023005421A (es) 2019-12-06 2021-12-02 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022012042A MX2022012042A (es) 2019-12-06 2021-12-02 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2023014077A MX2023014077A (es) 2019-12-06 2022-06-03 Composiciones de proteina anti-vegf y metodos para producir la misma.

Family Applications Before (6)

Application Number Title Priority Date Filing Date
MX2021014862A MX2021014862A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022006788A MX2022006788A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2021014863A MX2021014863A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022006759A MX2022006759A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022006758A MX2022006758A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022006760A MX2022006760A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2023005421A MX2023005421A (es) 2019-12-06 2021-12-02 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022012042A MX2022012042A (es) 2019-12-06 2021-12-02 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2023014077A MX2023014077A (es) 2019-12-06 2022-06-03 Composiciones de proteina anti-vegf y metodos para producir la misma.

Country Status (18)

Country Link
US (34) US11098112B2 (es)
EP (6) EP3906303A1 (es)
JP (12) JP2022548197A (es)
KR (12) KR20230051296A (es)
CN (6) CN114423783A (es)
AU (12) AU2020396490C1 (es)
BR (5) BR112021025359A2 (es)
CA (4) CA3159586A1 (es)
CO (6) CO2021018203A2 (es)
IL (16) IL288351B2 (es)
MX (10) MX2021014862A (es)
MY (12) MY193353A (es)
NZ (6) NZ781138A (es)
PE (6) PE20221261A1 (es)
SG (6) SG11202110968VA (es)
TW (6) TW202128991A (es)
WO (7) WO2021112927A1 (es)
ZA (4) ZA202107644B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021112927A1 (en) * 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
WO2022234412A1 (en) 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
WO2023039457A1 (en) * 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
CN116162148A (zh) * 2021-11-24 2023-05-26 苏州光度生物科技有限公司 多特异性配体结合分子及其应用
WO2023137143A1 (en) * 2022-01-14 2023-07-20 Shattuck Labs, Inc. Methods of contaminant removal from protein isolates
WO2023230486A2 (en) * 2022-05-23 2023-11-30 Inhalon Biopharma, Inc. Compositions and methods for inhalable therapeutics
WO2024114799A1 (zh) * 2022-12-01 2024-06-06 信达生物制药(苏州)有限公司 三特异性融合蛋白及其用途
US20240229002A1 (en) * 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof
KR20240115650A (ko) 2023-01-19 2024-07-26 주식회사 스카이테라퓨틱스 티로신 키나아제 억제제의 무정형 나노 분자회합체와 이를 포함하는 조성물 및 그의 제조방법

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1522343A (en) 1923-05-02 1925-01-06 Thom Clarence Magnetic separator
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
EP0283942B1 (en) 1987-03-24 1992-05-20 W.R. Grace & Co.-Conn. Basal nutrient medium for cell culture
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP2000517188A (ja) 1996-08-30 2000-12-26 ライフ テクノロジーズ，インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
SE519827C2 (sv) 1998-03-30 2003-04-15 Viranative Ab Näringsmedium innehållande metionin samt användning av detta
JP4723140B2 (ja) * 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
WO2001039793A2 (en) * 1999-11-30 2001-06-07 Smithkline Beecham P.L.C. Pharmaceutical compositions containing sema7a polypeptides
CN101255192A (zh) 2000-05-26 2008-09-03 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变体分子及其应用
CA2438148A1 (en) 2001-02-15 2002-08-29 Centocor, Inc. Chemically defined medium for cultured mammalian cells
JP2004533236A (ja) 2001-04-13 2004-11-04 ワイエス 化膿性連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｙｏｇｅｎｅｓ）の表面タンパク質
EP1404813A4 (en) 2001-06-13 2004-11-24 Genentech Inc METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US8777906B1 (en) 2002-01-24 2014-07-15 Robin Scott Gray Syringe with inspection window
ATE488600T1 (de) 2002-12-23 2010-12-15 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN100537751C (zh) 2004-05-12 2009-09-09 华东理工大学 一种适合中国仓鼠卵巢细胞培养的无血清培养基
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CA2585547A1 (en) 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
PT1861116E (pt) 2005-03-25 2015-11-04 Regeneron Pharma Formulações de antagonista do vegf
WO2006131347A2 (en) 2005-06-09 2006-12-14 Hansa Medical Ab Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
CN1778903A (zh) 2005-09-29 2006-05-31 华东理工大学 一种动物细胞高密度连续灌注培养方法
PL3121266T3 (pl) 2006-01-04 2020-07-13 Baxalta Incorporated Wolne od oligopeptydów pożywki do hodowli komórkowej
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
PT2495307T (pt) 2006-07-13 2018-05-10 Wyeth Llc Produção do fator ix de coagulação com padrão melhorado de glicosilação
CN101541825B (zh) * 2006-08-28 2013-08-14 阿雷斯贸易股份有限公司 Fc融合蛋白的纯化方法
AU2007294122B2 (en) 2006-09-10 2013-03-07 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
SG174804A1 (es) 2006-09-13 2011-10-28 Abbott Lab
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
JP2010524467A (ja) 2007-04-16 2010-07-22 モメンタ ファーマシューティカルズ インコーポレイテッド 規定の糖タンパク質産物および関連の方法
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
JP2010536355A (ja) 2007-08-31 2010-12-02 エフ．ホフマン−ラ ロシュ アーゲー グリコシル化プロファイル分析
CN101903401B (zh) * 2007-12-21 2013-06-05 罗切格利卡特公司 抗体的稳定性试验
KR101415099B1 (ko) 2008-07-31 2014-07-08 고쿠리츠 다이가쿠 호진 교토 다이가쿠 불포화 폴리에스테르 수지와 마이크로피브릴화 식물 섬유를 함유하는 성형 재료
CA2737580A1 (en) 2008-09-26 2010-04-01 Schering Corporation High titer antibody production
US20120329709A1 (en) 2009-05-26 2012-12-27 Brian Edward Collins Production of glycoproteins
EP3916011A1 (en) 2009-06-26 2021-12-01 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
KR101574056B1 (ko) 2009-07-31 2015-12-02 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
LT3037104T (lt) * 2009-10-20 2020-09-10 Abbvie Inc. Anti-il-13 antikūnų izoliavimas ir gryninimas, naudojant afininę baltymo a chromatografiją
EP2325296A1 (en) 2009-11-20 2011-05-25 LEK Pharmaceuticals d.d. Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
KR20220097542A (ko) 2011-01-13 2022-07-07 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN102653729B (zh) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 一种用于中国仓鼠卵巢细胞的培养基
WO2012140487A1 (en) 2011-04-11 2012-10-18 Cellcura Asa Protein-free culture media products for manufacturing viral-based vaccines
KR101591671B1 (ko) 2011-04-29 2016-02-04 바이오콘 리서치 리미티드 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법
CN105189735B (zh) 2011-04-29 2019-04-12 拜康研究有限公司 在培养期间减少乳酸累积的方法和生产多肽的方法
CA2777978A1 (en) 2011-05-27 2012-11-27 Abbott Biotherapeutics Corp. Dac hyp compositions and methods
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
WO2013054250A1 (en) * 2011-10-10 2013-04-18 Dr Reddy's Laboratories Limited Purification method
KR101759694B1 (ko) 2011-10-28 2017-07-19 인테그리티 바이오, 아이엔씨. 아미노산을 함유하는 단백질 제제
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
CN102757496B (zh) * 2012-06-07 2014-06-18 山东泉港药业有限公司 一种抗vegf抗体片段的纯化制备方法
AU2012101678B4 (en) * 2012-07-03 2013-01-24 Novartis Ag Use of device
EP2875131B1 (en) * 2012-07-18 2018-03-14 Siemens Healthcare Diagnostics Inc. A method of normalizing biological samples
JP2015526430A (ja) * 2012-08-02 2015-09-10 サノフイ アフリベルセプトまたはｚｉｖ−アフリベルセプトを含む製造物品
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2722673B1 (en) * 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
US9365314B2 (en) * 2012-11-16 2016-06-14 Owens-Brockway Glass Container Inc. Product and package with a photosensitive use-evident feature
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
CN103146648A (zh) 2013-03-14 2013-06-12 北京京蒙高科干细胞技术有限公司 一种无动物源的淋巴细胞无血清培养基
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
SG10201912621TA (en) 2013-03-15 2020-02-27 Genentech Inc Cell culture compositions with antioxidants and methods for polypeptide production
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CA2906175C (en) * 2013-03-15 2022-12-13 Daniel J. Capon Hybrid immunoglobulin containing non-peptidyl linkage
CN103773732B (zh) 2013-06-08 2016-05-11 李锋 一种化学成分确定的培养基、其应用及大规模培养哺乳动物细胞的生产工艺
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015058369A1 (en) 2013-10-23 2015-04-30 Sanofi (China) Investment Co., Ltd. Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
AU2015214245B2 (en) 2014-02-04 2020-09-10 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CN104073464A (zh) 2014-07-08 2014-10-01 西藏天虹科技股份有限责任公司 一种cho细胞无血清培养基及其制备方法
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
EP3268389B1 (en) * 2015-03-12 2020-09-30 Medimmune, LLC Method of purifying albumin-fusion proteins
KR101867134B1 (ko) 2015-03-23 2018-06-12 한양대학교 산학협력단 포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
SG11201705743YA (en) 2015-04-01 2017-08-30 Boehringer Ingelheim Int Cell culture medium
CN105002242A (zh) 2015-07-23 2015-10-28 苏州康聚生物科技有限公司 用于cho细胞中高效表达重组人促甲状腺激素的无血清培养基及其应用
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法
JP6950957B2 (ja) * 2015-10-22 2021-10-13 プロテノバ株式会社 イムノグロブリン結合ポリペプチド
CA3005117C (en) * 2015-11-18 2023-01-24 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
CA3005692A1 (en) 2015-11-18 2017-05-26 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
CN105368808B (zh) * 2015-11-30 2019-04-30 苏州康聚生物科技有限公司 一种IdeS蛋白酶、其制备方法及应用
JP2019503363A (ja) 2015-12-22 2019-02-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 急性リンパ芽球性白血病を治療するための二重特異性の抗ｃｄ２０／抗ｃｄ３抗体
WO2017112775A1 (en) 2015-12-22 2017-06-29 Regeneron Pharmaceuticals, Inc. Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
EP3196646B1 (en) * 2016-01-19 2019-12-18 Hexal AG Methods of mapping protein variants
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
WO2017168296A1 (en) * 2016-03-29 2017-10-05 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
CN106279412A (zh) * 2016-09-12 2017-01-04 广东东阳光药业有限公司 一种抗vegf类单克隆抗体的纯化方法
CA3037732A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
RS63660B1 (sr) 2016-09-23 2022-11-30 Regeneron Pharma Anti-muc16 (mucin 16) antitela
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN116327963A (zh) * 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
HRP20221071T1 (hr) * 2016-12-23 2022-11-11 Serum Institute Of India Private Limited Postupci za povećanje produktivnosti antitijela u kulturi stanica sisavaca i smanjenje agregacije tokom nizvodne obrade, postupci formulacije i rezultirajuće stabilne formulacije antitijela
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
WO2018170488A1 (en) * 2017-03-17 2018-09-20 Gilead Sciences, Inc. Method of purifying an antibody
KR101861163B1 (ko) 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
WO2019036626A1 (en) * 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. PROCESS FOR PURIFYING GLYCOSYLATED PROTEIN FROM GALECTINES AND OTHER HOST CELL CONTAMINANTS
AU2018350990A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
JP7183268B2 (ja) * 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
CN109929038B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Vegf捕获剂融合蛋白的纯化方法
CN109929027B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 采用线性洗脱步骤的重组融合蛋白纯化方法
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
US11667702B2 (en) * 2018-03-08 2023-06-06 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
EP3765856B1 (en) 2018-03-13 2023-09-27 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
MA52570A (fr) 2018-05-10 2021-03-17 Regeneron Pharma Formulations contenant des protéines de fusion du récepteur vegf à haute concentration
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
SG11202107762QA (en) 2019-01-30 2021-08-30 Amgen Inc Aflibercept attributes and methods of characterizing and modifying thereof
US20220204920A1 (en) 2019-05-16 2022-06-30 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
WO2021112927A1 (en) * 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same

Also Published As

Publication number Publication date
IL296512B1 (en) 2023-08-01
US20240309064A1 (en) 2024-09-19
US20230041349A1 (en) 2023-02-09
AU2020398830B2 (en) 2022-12-15
CO2021018192A2 (es) 2022-01-17
WO2021112928A1 (en) 2021-06-10
US11472861B2 (en) 2022-10-18
US20220009998A1 (en) 2022-01-13
IL309560A (en) 2024-02-01
NZ781142A (en) 2023-05-26
AU2020397803A1 (en) 2021-10-28
NZ781145A (en) 2023-05-26
US20210284684A1 (en) 2021-09-16
US20230119662A1 (en) 2023-04-20
US20210206832A1 (en) 2021-07-08
IL288360B1 (en) 2023-05-01
MY193349A (en) 2022-10-06
IL288352B (en) 2022-11-01
US20220033472A1 (en) 2022-02-03
CN114423783A (zh) 2022-04-29
US20210206833A1 (en) 2021-07-08
US20220048975A1 (en) 2022-02-17
CA3172631A1 (en) 2021-06-10
US12054533B2 (en) 2024-08-06
IL288351B1 (en) 2024-01-01
US12049489B2 (en) 2024-07-30
US20220127331A1 (en) 2022-04-28
IL304390A (en) 2023-09-01
KR20240005206A (ko) 2024-01-11
JP2023171771A (ja) 2023-12-05
CN114206924A (zh) 2022-03-18
IL296893B2 (en) 2024-05-01
CO2021018234A2 (es) 2022-01-17
PE20221789A1 (es) 2022-11-25
MX2021014862A (es) 2022-09-27
PE20221770A1 (es) 2022-11-11
US11548932B2 (en) 2023-01-10
CO2021018214A2 (es) 2022-01-17
IL296864B2 (en) 2023-10-01
US11753459B2 (en) 2023-09-12
MX2022012042A (es) 2022-10-27
WO2021112925A1 (en) 2021-06-10
NZ781143A (en) 2023-05-26
AU2023201590A1 (en) 2023-04-13
CA3129193A1 (en) 2021-06-10
IL296893B1 (en) 2024-01-01
MX2022006758A (es) 2023-01-30
MY193351A (en) 2022-10-06
KR20230152810A (ko) 2023-11-03
NZ781137A (en) 2023-05-26
ZA202107647B (en) 2022-03-30
PE20221788A1 (es) 2022-11-25
AU2020398830C1 (en) 2023-04-27
IL301888A (en) 2023-06-01
US12054532B2 (en) 2024-08-06
IL296512B2 (en) 2023-12-01
MY193350A (en) 2022-10-06
US11440950B2 (en) 2022-09-13
KR20220038062A (ko) 2022-03-25
US11732025B2 (en) 2023-08-22
US11505593B2 (en) 2022-11-22
IL288351B2 (en) 2024-05-01
KR20220035393A (ko) 2022-03-22
SG11202110955VA (en) 2021-10-28
IL302921A (en) 2023-07-01
EP3931204A1 (en) 2022-01-05
EP3906302A1 (en) 2021-11-10
IL288351A (en) 2022-01-01
KR20230051297A (ko) 2023-04-17
US11306135B2 (en) 2022-04-19
KR20240005222A (ko) 2024-01-11
IL296512A (en) 2022-11-01
MY190623A (en) 2022-04-27
IL296864B1 (en) 2023-06-01
JP2022547651A (ja) 2022-11-15
JP2024009950A (ja) 2024-01-23
IL288357B (en) 2022-11-01
KR102519236B1 (ko) 2023-04-10
SG11202110968VA (en) 2021-10-28
AU2023201585A1 (en) 2023-04-13
TW202128991A (zh) 2021-08-01
BR112021025158A2 (pt) 2022-06-21
IL288367B2 (en) 2023-02-01
AU2020397865B2 (en) 2022-12-15
CN114206907A (zh) 2022-03-18
US20210171570A1 (en) 2021-06-10
ZA202107646B (en) 2022-03-30
NZ781136A (en) 2023-05-26
US20230068199A1 (en) 2023-03-02
BR112021025769A2 (pt) 2022-04-12
WO2021112924A1 (en) 2021-06-10
CA3159586A1 (en) 2021-06-10
AU2020396490B2 (en) 2022-12-15
US11958894B2 (en) 2024-04-16
US11053280B2 (en) 2021-07-06
AU2023201586A1 (en) 2023-04-13
US20240317835A1 (en) 2024-09-26
PE20221791A1 (es) 2022-11-25
MX2022006759A (es) 2023-01-30
US20230357357A1 (en) 2023-11-09
AU2020397803C1 (en) 2023-05-11
KR20230051296A (ko) 2023-04-17
US20210214430A1 (en) 2021-07-15
TW202128745A (zh) 2021-08-01
US20220033471A1 (en) 2022-02-03
KR20220041083A (ko) 2022-03-31
MX2023005421A (es) 2023-05-23
EP3931303A1 (en) 2022-01-05
IL288357B2 (en) 2023-03-01
CO2021018181A2 (es) 2022-01-17
SG11202110958QA (en) 2021-10-28
IL288352A (en) 2022-01-01
IL288360A (en) 2022-01-01
US20240067701A1 (en) 2024-02-29
MY193354A (en) 2022-10-06
IL288367A (en) 2022-01-01
US20220009997A1 (en) 2022-01-13
CA3172631C (en) 2024-01-02
AU2020398547B2 (en) 2022-12-22
CN114206914A (zh) 2022-03-18
CA3172625A1 (en) 2021-06-10
BR112021025438A2 (pt) 2022-06-21
US11649273B2 (en) 2023-05-16
SG11202110953UA (en) 2021-10-28
US11098311B2 (en) 2021-08-24
JP2022547652A (ja) 2022-11-15
MY190626A (en) 2022-04-27
US11459374B2 (en) 2022-10-04
MX2023014077A (es) 2023-12-11
AU2020398125A1 (en) 2021-10-28
MY190625A (en) 2022-04-27
JP2024119936A (ja) 2024-09-03
AU2020398547A1 (en) 2021-10-28
JP2022550930A (ja) 2022-12-06
AU2020398547C1 (en) 2023-05-11
US20230331812A1 (en) 2023-10-19
MY193355A (en) 2022-10-06
CN114401994A (zh) 2022-04-26
JP2022552052A (ja) 2022-12-15
NZ781138A (en) 2023-05-26
US20220389081A1 (en) 2022-12-08
JP2024026116A (ja) 2024-02-28
WO2021112923A1 (en) 2021-06-10
US20210214733A1 (en) 2021-07-15
IL288355A (en) 2022-01-01
US20210371501A1 (en) 2021-12-02
AU2020397865A1 (en) 2021-10-28
TW202128744A (zh) 2021-08-01
BR112021025359A2 (pt) 2022-06-21
PE20221790A1 (es) 2022-11-25
US11505594B2 (en) 2022-11-22
US11459373B2 (en) 2022-10-04
IL296863B1 (en) 2023-06-01
US20220098280A1 (en) 2022-03-31
US20210171605A1 (en) 2021-06-10
IL288355B (en) 2022-11-01
WO2021112926A1 (en) 2021-06-10
MX2022006788A (es) 2022-07-11
AU2023201748A1 (en) 2023-06-01
US11542317B1 (en) 2023-01-03
US12012445B2 (en) 2024-06-18
AU2020396490A1 (en) 2021-10-28
US12012444B2 (en) 2024-06-18
KR20220038347A (ko) 2022-03-28
AU2023201589A1 (en) 2023-04-06
US20220227835A1 (en) 2022-07-21
JP2023179531A (ja) 2023-12-19
WO2021112929A1 (en) 2021-06-10
US11180540B2 (en) 2021-11-23
KR20220038349A (ko) 2022-03-28
SG11202110964QA (en) 2021-10-28
SG11202110972UA (en) 2021-10-28
US11104715B2 (en) 2021-08-31
ZA202107644B (en) 2022-03-30
EP3906250A1 (en) 2021-11-10
US11098112B2 (en) 2021-08-24
PE20221261A1 (es) 2022-08-16
US20240294606A1 (en) 2024-09-05
IL288352B2 (en) 2023-03-01
US12077570B2 (en) 2024-09-03
TW202122417A (zh) 2021-06-16
US11407813B2 (en) 2022-08-09
IL288367B (en) 2022-10-01
IL309491A (en) 2024-02-01
US20220235116A1 (en) 2022-07-28
TW202134256A (zh) 2021-09-16
CA3129193C (en) 2022-10-04
AU2020397865C1 (en) 2023-04-27
BR112021025432A2 (pt) 2022-06-21
IL296863B2 (en) 2023-10-01
TW202128743A (zh) 2021-08-01
US20230272044A1 (en) 2023-08-31
US11485770B2 (en) 2022-11-01
IL296863A (en) 2022-11-01
US11535663B2 (en) 2022-12-27
AU2023201588A1 (en) 2023-04-13
KR102619866B1 (ko) 2024-01-04
US11299532B2 (en) 2022-04-12
IL302538A (en) 2023-07-01
CN114206925A (zh) 2022-03-18
US20220009999A1 (en) 2022-01-13
EP3906303A1 (en) 2021-11-10
MY190624A (en) 2022-04-27
US20230235019A1 (en) 2023-07-27
CO2021018203A2 (es) 2022-01-17
WO2021112927A1 (en) 2021-06-10
US11174283B2 (en) 2021-11-16
AU2020398830A1 (en) 2021-10-28
MY190627A (en) 2022-04-27
AU2020396490C1 (en) 2023-04-27
JP2022548818A (ja) 2022-11-22
IL288357A (en) 2022-01-01
JP2024009949A (ja) 2024-01-23
ZA202208710B (en) 2024-09-25
US20220227836A1 (en) 2022-07-21
KR20240007293A (ko) 2024-01-16
IL288360B2 (en) 2023-09-01
EP3906249A1 (en) 2021-11-10
MX2021014863A (es) 2022-09-28
AU2020398125C1 (en) 2023-05-11
MY193353A (en) 2022-10-06
MX2022006760A (es) 2023-01-30
KR20220038348A (ko) 2022-03-28
AU2020397803B2 (en) 2022-12-15
BR112022001016A2 (pt) 2022-08-16
AU2020398125B2 (en) 2022-12-15
MY190686A (en) 2022-05-10
US11186625B2 (en) 2021-11-30
CO2022000660A2 (es) 2022-01-28
KR102519234B1 (ko) 2023-04-10
US20220162289A1 (en) 2022-05-26
JP2022548197A (ja) 2022-11-17
US20220396608A1 (en) 2022-12-15
US20220275054A1 (en) 2022-09-01
US11286290B2 (en) 2022-03-29
IL288355B2 (en) 2023-03-01
IL296864A (en) 2022-11-01
IL296893A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
ZA202208710B (en) Anti-vegf protein compositions and methods for producing the same
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
SG10201914126RA (en) Anti-ox40 antibodies and their uses
MY195442A (en) Anti-CD40 Antibodies and Their Uses